Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1785 Target Snapshot

Endothelin receptor type B · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,746Compounds
239Assays
7Approved Drugs
1,500.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Endothelin receptor type B shows late clinical disease relevance led by heart failure. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P24530. Start with heart failure, then reuse UniProt P24530 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with heart failure, then reuse UniProt P24530 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
heart failure

Endothelin receptor type B shows late clinical disease relevance led by heart failure. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with heart failure because it currently carries late clinical support. Linked drugs include TEZOSENTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Endothelin receptor type B as ChEMBL target CHEMBL1785, mapped to UniProt P24530. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Endothelin receptor type B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1785
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24530
Endothelin receptor type B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Endothelin receptor type B is the right protein anchor across sources, using UniProt P24530 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why heart failure is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEndothelin receptor type B
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP24530
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEndothelin receptor type B
UniProt AccessionP24530
Component TypeProtein
Sequence Length442 aa

Endothelin receptor type B

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Endothelin receptor type B, mapped to UniProt P24530. Sequence length is 442 aa.

Mapped IDP24530
Review nameEndothelin receptor type B
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Endothelin receptor type B shows late clinical disease relevance led by heart failure. 2 more disease programs remain visible in the same review block.

Late clinical Phase III
heart failure
1 linked drug · 1 direct · 1 efficacy
Linked drugTEZOSENTAN
Late clinical Phase III
hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugDARUSENTAN
Clinical signal Phase II
pulmonary arterial hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugTEZOSENTAN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with heart failure because it currently carries late clinical support. Linked drugs include TEZOSENTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseheart failure
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
8
Phase III
4
Phase II
2
Phase 0.5
Assay Mix

Activity Type Distribution

IC501,278.0
KI215.0
EC502.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1790180 10.77 Ki 0.017 Preclinical
CHEMBL1790180 10.52 IC50 0.03 Preclinical
CHEMBL437472 10.22 Ki 0.06 Clinical
CHEMBL3980643 10.0 IC50 0.1 Preclinical
CHEMBL437472 9.89 IC50 0.13 Clinical
CHEMBL325581 9.85 IC50 0.14 Preclinical
CHEMBL310039 9.85 Ki 0.14 Preclinical
CHEMBL419367 9.7 IC50 0.2 Preclinical
CHEMBL2165327 9.68 IC50 0.208 Preclinical
CHEMBL433106 9.68 Ki 0.21 Preclinical
Distribution

pChEMBL Value Distribution

152
5.0
191
5.5
201
6.0
146
6.5
116
7.0
88
7.5
58
8.0
28
8.5
25
9.0
15
9.5
pChEMBL
Approved Drugs

Approved Drugs

APROCITENTAN
CHEMBL2165326
Approved 2024
Properties Compare Identifier
MACITENTAN
CHEMBL2103873
Approved 2010
Properties Compare Identifier
AMBRISENTAN
CHEMBL1111
Approved 2007
Properties Compare Identifier
BOSENTAN
CHEMBL957
Approved 2001
Properties Compare Identifier
Assay Landscape

Assay Landscape

239
Total Assays
1,059
Tested Compounds
2
Assay Types
Binding — 209 assays, 1,059 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 117 387 6.2
cell-based format 68 543 6.1
tissue-based format 9 36 5.9
assay format 8 64 6.3
cell membrane format 6 28 6.4
organism-based format 1 1 6.0
Functional — 30 assays, 135 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 15 30 6.8
cell-based format 12 101 6.9
cell membrane format 2 3 8.2
single protein format 1 1 9.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine